Emerging biotech organizations have had to become both resourceful and creative since the start of the COVID-19 pandemic. At the same time, Big Pharma and the medical device firms have turned around COVID-19 diagnostics, vaccines, and therapeutics at a stunningly impressive pace. The pressure on emerging and small biotech companies to do more with less and maximize results is only projected to continue. Precision’s Ross Maclean and co-author Liz Turner identify seven key attributes that favor the smaller biotech.
